首页
学术期刊
论文检测
AIGC检测
热点
更多
数据
ACCEPTANCE OF SURROGATE ENDPOINTS BY HTA AGENCIES IN EUROPE
被引:0
|
作者
:
Es-Skali, I. J.
论文数:
0
引用数:
0
h-index:
0
机构:
Quintiles, Hoofddorp, Netherlands
Quintiles, Hoofddorp, Netherlands
Es-Skali, I. J.
[
1
]
Nijhuis, T.
论文数:
0
引用数:
0
h-index:
0
机构:
Quintiles, Hoofddorp, Netherlands
Quintiles, Hoofddorp, Netherlands
Nijhuis, T.
[
1
]
机构
:
[1]
Quintiles, Hoofddorp, Netherlands
来源
:
VALUE IN HEALTH
|
2013年
/ 16卷
/ 07期
关键词
:
D O I
:
10.1016/j.jval.2013.08.935
中图分类号
:
F [经济];
学科分类号
:
02 ;
摘要
:
引用
收藏
页码:A484 / A484
页数:1
相关论文
共 50 条
[1]
THE ASSESSMENT OF SURROGATE ENDPOINTS AND THEIR IMPACT ON HTA RECOMMENDATIONS
Foy, C.
论文数:
0
引用数:
0
h-index:
0
机构:
Mtech Access, Cambridge, England
Mtech Access, Cambridge, England
Foy, C.
Mathers, L.
论文数:
0
引用数:
0
h-index:
0
机构:
Mtech Access, East Kilbride, Scotland
Mtech Access, Cambridge, England
Mathers, L.
Khayat, E.
论文数:
0
引用数:
0
h-index:
0
机构:
Mtech Access, Cambridge, England
Mtech Access, Cambridge, England
Khayat, E.
[J].
VALUE IN HEALTH,
2022,
25
(12)
: S34
-
S34
[2]
VALIDATION OF SURROGATE ENDPOINTS IN MELANOMA THERAPIES AND USE IN HTA
Hopkinson, D.
论文数:
0
引用数:
0
h-index:
0
机构:
McCann Hlth, Macclesfield, Cheshire, England
McCann Hlth, Macclesfield, Cheshire, England
Hopkinson, D.
Chadwick, C.
论文数:
0
引用数:
0
h-index:
0
机构:
McCann Hlth, Macclesfield, Cheshire, England
McCann Hlth, Macclesfield, Cheshire, England
Chadwick, C.
Bibi, M.
论文数:
0
引用数:
0
h-index:
0
机构:
McCann Hlth, Macclesfield, Cheshire, England
McCann Hlth, Macclesfield, Cheshire, England
Bibi, M.
Bastian, A.
论文数:
0
引用数:
0
h-index:
0
机构:
Incyte Corp, Wilmington, DE USA
McCann Hlth, Macclesfield, Cheshire, England
Bastian, A.
[J].
VALUE IN HEALTH,
2017,
20
(09)
: A731
-
A731
[3]
Surrogate endpoints for HTA decisions of breast cancer drugs: utility and pitfalls
Wright, Kristin
论文数:
0
引用数:
0
h-index:
0
机构:
Queens Univ, Dept Oncol, Kingston, ON, Canada
Queens Univ, Dept Oncol, Kingston, ON, Canada
Wright, Kristin
论文数:
引用数:
h-index:
机构:
Mittal, Abhenil
Gyawali, Bishal
论文数:
0
引用数:
0
h-index:
0
机构:
Queens Univ, Dept Oncol, Kingston, ON, Canada
Queens Univ, Dept Publ Hlth Sci, Kingston, ON, Canada
Queens Univ, Div Canc Care & Epidemiol, Kingston, ON, Canada
Queens Univ, Dept Oncol, Kingston, ON, Canada
Gyawali, Bishal
[J].
CURRENT OPINION IN ONCOLOGY,
2023,
35
(06)
: 513
-
521
[4]
Differences In HTA Acceptance Rates Across Disease Areas: A Comparison Between Four HTA Agencies
Vadlamudi, N. K.
论文数:
0
引用数:
0
h-index:
0
机构:
Parexel Int, Hyderabad, Andhra Pradesh, India
Parexel Int, Hyderabad, Andhra Pradesh, India
Vadlamudi, N. K.
Griffiths, E. A.
论文数:
0
引用数:
0
h-index:
0
机构:
PAREXEL, London, England
Parexel Int, Hyderabad, Andhra Pradesh, India
Griffiths, E. A.
[J].
VALUE IN HEALTH,
2016,
19
(03)
: A287
-
A287
[5]
BRIDGING HTA AGENCIES ACROSS EUROPE: A SYSTEMATIC APPROACH TO CATEGORIZE EVOLVING AGENCIES
Nagy, L.
论文数:
0
引用数:
0
h-index:
0
机构:
MSD Pharma Hungary Ltd, Budapest, Hungary
MSD Pharma Hungary Ltd, Budapest, Hungary
Nagy, L.
Kamal-Bahl, S.
论文数:
0
引用数:
0
h-index:
0
机构:
Merck & Co Inc, Sumneytown Pike, PA USA
MSD Pharma Hungary Ltd, Budapest, Hungary
Kamal-Bahl, S.
Brandtmueller, A.
论文数:
0
引用数:
0
h-index:
0
机构:
MSD Pharma Hungary, Budapest, Hungary
MSD Pharma Hungary Ltd, Budapest, Hungary
Brandtmueller, A.
[J].
VALUE IN HEALTH,
2013,
16
(03)
: A268
-
A268
[6]
FDA acceptance of surrogate endpoints in later lines of therapy
Chen, Emerson Yu-sheng
论文数:
0
引用数:
0
h-index:
0
机构:
Oregon Hlth & Sci Univ, Portland, OR 97201 USA
Oregon Hlth & Sci Univ, Portland, OR 97201 USA
Chen, Emerson Yu-sheng
Joshi, Sunil K.
论文数:
0
引用数:
0
h-index:
0
机构:
Oregon Hlth & Sci Univ, Portland, OR 97201 USA
Oregon Hlth & Sci Univ, Portland, OR 97201 USA
Joshi, Sunil K.
Prasad, Vinay
论文数:
0
引用数:
0
h-index:
0
机构:
Oregon Hlth & Sci Univ, Portland, OR 97201 USA
Oregon Hlth & Sci Univ, Portland, OR 97201 USA
Prasad, Vinay
[J].
JOURNAL OF CLINICAL ONCOLOGY,
2018,
36
(15)
[7]
Surrogate endpoints
Hill, C
论文数:
0
引用数:
0
h-index:
0
机构:
Inst Gustave Roussy, F-94805 Villejuif, France
Inst Gustave Roussy, F-94805 Villejuif, France
Hill, C
[J].
BULLETIN DU CANCER,
1999,
86
(7-8)
: 622
-
624
[8]
A cost-benefit approach to the regulation, qualification and acceptance of biomarkers and surrogate endpoints
Williams, S. A.
论文数:
0
引用数:
0
h-index:
0
机构:
Pfizer Inc, New London, CT USA
Williams, S. A.
Slavin, D. E.
论文数:
0
引用数:
0
h-index:
0
机构:
Pfizer Inc, New London, CT USA
Slavin, D. E.
Wagner, J. A.
论文数:
0
引用数:
0
h-index:
0
机构:
Pfizer Inc, New London, CT USA
Wagner, J. A.
Webster, C. J.
论文数:
0
引用数:
0
h-index:
0
机构:
Pfizer Inc, New London, CT USA
Webster, C. J.
[J].
ATHEROSCLEROSIS SUPPLEMENTS,
2006,
7
(03)
: 480
-
480
[9]
Three worlds of health technology assessment: explaining patterns of diffusion of HTA agencies in Europe
Loblova, Olga
论文数:
0
引用数:
0
h-index:
0
机构:
Cent European Univ, Sch Publ Policy, Nador Utca 9, H-1051 Budapest, Hungary
Cent European Univ, Sch Publ Policy, Nador Utca 9, H-1051 Budapest, Hungary
Loblova, Olga
[J].
HEALTH ECONOMICS POLICY AND LAW,
2016,
11
(03)
: 253
-
273
[10]
Surrogate endpoints and emerging surrogate endpoints for risk reduction of cardiovascular disease
Rasnake, Crystal M.
论文数:
0
引用数:
0
h-index:
0
机构:
US FDA, Nutr Programs Staff, College Pk, MD USA
US FDA, Nutr Programs Staff, College Pk, MD USA
Rasnake, Crystal M.
Trumbo, Paula R.
论文数:
0
引用数:
0
h-index:
0
机构:
US FDA, Nutr Programs Staff, College Pk, MD USA
US FDA, Nutr Programs Staff, College Pk, MD USA
Trumbo, Paula R.
Heinonen, Therese M.
论文数:
0
引用数:
0
h-index:
0
机构:
Montreal Heart Inst Coordinating Ctr, Montreal, PQ, Canada
US FDA, Nutr Programs Staff, College Pk, MD USA
Heinonen, Therese M.
[J].
NUTRITION REVIEWS,
2008,
66
(02)
: 76
-
81
←
1
2
3
4
5
→